Quick answer: Semaglutide begins acting in the body after the first dose, but visible weight loss usually develops gradually over months. During the first 16 weeks of injectable Wegovy treatment, the dose is typically increased in stages. These introductory doses are designed primarily to improve tolerability—not produce maximum weight loss immediately.

In the STEP 1 trial, adults receiving once-weekly semaglutide 2.4 mg plus lifestyle intervention lost an average of 14.9% of their starting weight after 68 weeks. Weight loss continued for many months and began leveling off around week 60.[1]

That trial average does not predict exactly what will happen to one person. Your dose, starting weight, diabetes status, food intake, physical activity, side effects and individual biology all influence the timeline.

Semaglutide timeline at a glance

Treatment period	What may be happening
Week 1	Medication exposure begins; appetite effects may be subtle or absent
Weeks 2–4	Early appetite or fullness changes may develop; scale changes remain unpredictable
Weeks 5–8	Dose may be increased if tolerated; some people begin seeing a clearer trend
Weeks 9–12	Appetite effects may become more consistent; gastrointestinal symptoms can reappear after escalation
Weeks 13–16	Many patients remain in dose escalation; cumulative weight loss may become easier to recognize
Months 4–6	A more meaningful trend commonly develops after adequate exposure
Months 6–12	Weight may continue declining, although the rate commonly slows
Around one year and beyond	A plateau may emerge; treatment may still help maintain the loss

This timeline is educational, not a personalized dosing schedule. Follow the instructions for your exact formulation and prescription.

How quickly does semaglutide start working?

Semaglutide has a long half-life and is designed to remain active between doses. It activates glucagon-like peptide-1, or GLP-1, receptors involved in appetite, satiety, digestion and glucose-dependent insulin release.

The medication may begin influencing appetite after the first dose, but “working” can mean several things:

• Feeling full sooner
• Thinking about food less frequently
• Having fewer cravings
• Eating smaller portions
• Improving blood-sugar measurements
• Losing measurable body weight
• Maintaining weight already lost

These effects do not always appear at the same time. A person may notice reduced appetite before the scale changes. Another person may not feel a dramatic appetite difference but may gradually eat less and lose weight.

Why there is no reliable pound-per-week prediction

It is tempting to ask how many pounds semaglutide should produce each week, but clinical trials report group averages over months—not a guaranteed weekly rate.

Short-term scale weight is affected by:

• Water retention
• Sodium and carbohydrate intake
• Constipation
• Menstrual-cycle changes
• Recent exercise
• Time of day
• Clothing
• Food and fluid still being digested

A person can lose body fat during a week in which scale weight remains unchanged. Conversely, a rapid early drop can reflect water loss rather than an unusually large reduction in fat.

Evaluate four-week trends instead of expecting the scale to fall every seven days.

Week 1: The medication is beginning to build up

During the first week, some people notice:

• Earlier fullness during meals
• Reduced appetite
• Mild nausea
• Burping or reflux
• Constipation or diarrhea
• No noticeable difference

All of these experiences can occur. Not feeling appetite suppression after the first injection does not prove semaglutide will fail.

The introductory dose is intentionally low. Do not take another dose early or increase it because you do not immediately feel an effect.

What to focus on

• Learn the correct injection technique.
• Establish a consistent dosing day.
• Eat slowly and stop when comfortably full.
• Maintain adequate hydration.
• Record side effects.
• Confirm missed-dose instructions for your product.

Seek advice if you are unsure whether an injection was completed correctly. Do not automatically repeat it because doing so could result in excessive dosing.

Weeks 2–4: Early appetite changes may become noticeable

Semaglutide exposure accumulates with repeated weekly doses. During the first month, some patients begin noticing more consistent satiety or fewer cravings.

Weight change remains highly variable. One person may lose several pounds, while another may have little measurable change.

Common gastrointestinal effects include:

• Nausea
• Abdominal discomfort
• Constipation
• Diarrhea
• Reflux
• Reduced appetite

These symptoms are not required for the medication to work. Severe nausea is not evidence of better fat loss.

What to focus on

Build a repeatable eating pattern rather than pursuing an extreme diet:

• Include a protein source with meals.
• Choose fiber-containing foods as tolerated.
• Limit calorie-dense drinks.
• Use smaller portions when fullness occurs quickly.
• Avoid forcing yourself to finish large meals.
• Increase activity gradually if medically appropriate.

Persistent vomiting, inability to drink or signs of dehydration require medical attention.

Weeks 5–8: Dose escalation may change appetite and side effects

If treatment is tolerated, the prescribing plan may call for a dose increase. Appetite suppression may become more noticeable, but gastrointestinal symptoms can also temporarily return after an escalation.

Do not compare your response with someone taking a higher dose. Dose escalation is individualized, and reaching the highest dose quickly is not the goal.

What may be normal

• Weight fluctuating from week to week
• Gradual rather than dramatic loss
• Appetite suppression varying during the week
• Temporary constipation
• A brief increase in nausea after escalation

Contact your prescriber if

• Side effects interfere with eating or drinking.
• You are uncertain about the next dose.
• You missed multiple doses.
• You want to increase early.
• You are using a compounded product with unclear concentration or instructions.

Weeks 9–12: A trend may become easier to recognize

By the third month, some people can see a clearer downward trend. Others are still using escalation doses and may not yet have experienced their full response.

Look beyond a single number. Useful measures include:

• Percentage of starting weight lost
• Four-week weight trend
• Waist circumference
• Appetite and craving control
• Blood pressure
• Blood-sugar measurements when applicable
• Exercise tolerance
• Changes in sleep or mobility

For example, a person who began at 250 pounds and now weighs 242.5 pounds has lost 3% of their starting weight, even though the change may feel modest compared with online transformations.

Weeks 13–16: Approaching a maintenance phase

For traditional injectable Wegovy escalation, week 16 marks the end of the planned stepwise titration period for many patients. Some people need a slower schedule because of adverse effects.

An introductory dose should not be evaluated as though it were the full maintenance treatment. Conversely, no patient should increase the dose merely to match a generic timeline.

This is a useful time to review

• Whether doses were taken consistently
• Whether the injection technique is correct
• Side effects and bowel habits
• Food and beverage patterns
• Daily movement and resistance exercise
• Sleep
• Other medications that may affect weight
• Whether continuing escalation is appropriate

The prescriber may delay escalation, continue a tolerated maintenance dose or adjust the treatment plan based on the individual situation.

Months 4–6: Meaningful weight loss may become clearer

By this period, many patients have had more time at therapeutically relevant doses. A sustained trend may become easier to distinguish from daily fluctuations.

However, average trial results should still be interpreted carefully. STEP 1 participants received semaglutide plus regular counseling about reduced calorie intake and physical activity.[1] The medication was not studied as a replacement for nutrition or activity.

Why results differ

Two people using the same medication can have different outcomes because of:

• Starting body weight
• Dose and treatment duration
• Type 2 diabetes
• Food intake
• Physical activity
• Sleep quality
• Weight-promoting medications
• Medical conditions
• Treatment interruptions
• Individual biological response

People with type 2 diabetes have generally experienced less average weight loss in semaglutide obesity trials than participants without diabetes.[2]

Months 6–12: Weight may continue declining more slowly

Weight loss often continues after six months, but it usually does not maintain the same rate indefinitely.

As body weight decreases:

• A smaller body needs fewer calories.
• Resting energy expenditure may decline.
• Early fluid changes no longer contribute.
• Appetite-regulating biology may resist additional loss.
• The same eating pattern may create a smaller calorie deficit.

In STEP 1, average weight continued declining for many months before approaching a plateau around week 60.[1] In STEP 5, semaglutide-supported weight loss was largely maintained through two years when treatment continued.[3]

Slowing down therefore does not automatically mean the medication stopped working.

After one year: Plateau or maintenance

A plateau generally means that the weight trend has remained relatively stable for several weeks—not that the scale failed to change for a few days.

A plateau can represent:

• Normal biological adaptation
• A smaller calorie deficit at a lower weight
• Reduced daily movement
• Increased portions or liquid calories
• Constipation or water retention
• An inconsistent medication supply
• Maximum individual response
• Successful maintenance of prior loss

Maintaining a clinically meaningful reduction is a valuable outcome. Without treatment, some patients might otherwise regain weight.

A prescriber may review the dose, adherence, nutrition, activity, medications, sleep and possible medical contributors before deciding that semaglutide is providing inadequate benefit.

What percentage of body weight might you lose?

STEP 1 included 1,961 adults with overweight or obesity who did not have diabetes. After 68 weeks:[1]

• Average weight change with semaglutide was -14.9%.
• Average weight change with placebo was -2.4%.
• Approximately 86% of participants assigned to semaglutide lost at least 5%.
• Approximately 69% lost at least 10%.
• Approximately 51% lost at least 15%.

These results reflect a clinical-trial population using semaglutide 2.4 mg plus lifestyle intervention. They are not guaranteed outcomes.

Starting weight	5% loss	10% loss	15% loss
180 lb	9 lb	18 lb	27 lb
200 lb	10 lb	20 lb	30 lb
250 lb	12.5 lb	25 lb	37.5 lb
300 lb	15 lb	30 lb	45 lb

These calculations provide perspective and should not be treated as required milestones.

When should you worry that semaglutide is not working?

Do not judge the full response during the first few introductory doses. Request a structured review when:

• You have used the medication consistently through the planned escalation period but see little meaningful change.
• Appetite and weight have not changed after adequate time at a therapeutic dose.
• Weight is increasing for several weeks.
• Medication supply problems repeatedly interrupt treatment.
• Side effects prevent reaching or maintaining an appropriate dose.
• You are unsure whether the medication is being stored or administered correctly.
• Hunger returns substantially after an earlier response.

A clinician may review adherence, dose, injection technique, nutrition, activity, sleep and other medical factors. Do not increase the dose or shorten the dosing interval independently.

Why weight may stall after initial success

A plateau after initial weight loss is common and usually has more than one possible explanation:

1. Your energy needs decreased as you lost weight.
2. Daily activity declined.
3. Portions or liquid calories gradually increased.
4. Constipation or water retention obscured fat loss.
5. Sleep or stress changed.
6. Another medication promotes weight gain.
7. A medical condition is contributing.
8. You reached your individual response limit.

The appropriate response is reassessment—not punishment, starvation or unsupervised dose escalation.

What happens if semaglutide is stopped?

Semaglutide’s appetite effects do not permanently remain after discontinuation.

In the STEP 1 extension, participants who stopped semaglutide regained approximately two-thirds of their previous weight loss during the following year.[4] This finding supports treating obesity as a chronic condition that may require long-term management.

Regain after discontinuation does not mean the patient failed. Before beginning treatment, discuss:

• Expected duration
• Insurance coverage
• Medication supply
• Long-term affordability
• Maintenance strategies
• What to do if treatment is interrupted

Never restart at a previous high dose after a prolonged interruption without asking the prescriber. Restarting too high can produce significant gastrointestinal effects.

How to track progress accurately

Use the following method:

1. Weigh at the same time and under similar conditions once or twice weekly.
2. Record a weekly average if weighing more frequently.
3. Measure waist circumference approximately monthly.
4. Document the date of each dose.
5. Record dose changes and missed doses.
6. Note appetite, cravings and adverse effects.
7. Review progress using percentages, not only pounds.

Percentage lost is calculated as:

Starting weight minus current weight, divided by starting weight, multiplied by 100.

Example:

A decrease from 250 to 235 pounds is:

(250 − 235) ÷ 250 × 100 = 6%

Protecting muscle during semaglutide weight loss

Weight reduction can include both fat and lean tissue. The goal is not simply to make the scale fall as quickly as possible.

Discuss an appropriate plan that may include:

• Adequate dietary protein
• Resistance exercise
• Regular walking or other aerobic activity
• Avoiding excessive calorie restriction
• Adequate hydration
• Evaluation of persistent weakness or fatigue

Protein requirements and exercise recommendations vary with age, kidney function, medical conditions and activity level.

When to seek urgent medical care

Seek prompt medical evaluation for:

• Severe or persistent abdominal pain
• Pain radiating to the back
• Repeated vomiting
• Inability to keep fluids down
• Very little urination
• Severe weakness, fainting or confusion
• Yellow skin or eyes
• Facial or throat swelling
• Difficulty breathing
• Severe symptoms of low blood sugar
• Sudden vision changes

Rapid weight loss accompanied by persistent vomiting or inability to eat is not a desirable treatment result.

Frequently asked questions

Can semaglutide work during the first week?

It can begin influencing appetite during the first week, but some people notice no early effect. Lack of immediate appetite suppression does not predict treatment failure.

How much weight should I lose during the first month?

There is no dependable first-month target. Many patients are still using the lowest introductory dose. Short-term weight also fluctuates because of water, bowel contents and other factors.

When does semaglutide reach its full effect?

The effect develops gradually as doses accumulate and are increased. Weight loss in major trials continued over many months rather than peaking immediately.

Is losing no weight for two weeks a plateau?

Usually not. Two weeks may be too short to distinguish a true plateau from normal fluctuation. Review at least a four-week trend.

Does more nausea mean greater weight loss?

No. Severe gastrointestinal symptoms are adverse effects, not evidence that treatment is working better.

Should I increase the dose if my appetite returns?

Not without speaking with your prescriber. Appetite can vary, and dose decisions should consider your current formulation, schedule, response and side effects.

Can I take semaglutide and tirzepatide together?

These medications should not be combined for weight loss. Combining incretin-based medications can increase risk without established added benefit.

Bottom line

Semaglutide begins acting after the first dose, but its weight-loss effect usually unfolds over months.

A realistic timeline is:

• First month: Learn the treatment routine and assess tolerability.
• Months 2–4: Dose escalation continues and a weight trend may emerge.
• Months 4–6: The response may become easier to evaluate.
• Months 6–12: Weight may continue declining at a slower rate.
• Around one year and beyond: A plateau or maintenance phase is common.

Do not use another person’s weekly results as your required timeline. Follow the prescribed schedule, track longer-term trends and review inadequate response or troublesome side effects with your clinician.

---

Medical review: Mark Aquino, MSN, APRN, FNP-C, board-certified family nurse practitioner.

Medical disclaimer: This article provides general educational information and is not individualized medical advice. Semaglutide requires evaluation, prescribing and monitoring by a qualified healthcare professional. Do not start, stop, combine or change the dose of a prescription medication based solely on online information.

References

1. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
2. Davies M, Færch L, Jeppesen OK, et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity and type 2 diabetes: the STEP 2 trial. Lancet. 2021;397(10278):971-984. doi:10.1016/S0140-6736(21)00213-0.
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
4. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725.